این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۸، شماره ۳، صفحات ۲۴-۲۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Does Chemotherapy Change Expression of VEGF A&C and MVD in Acute Myeloid Leukemia?
چکیده انگلیسی مقاله Introduction: Acute Myeloid Leukemia is a malignant transformation of hematopoietic tissue, bone marrow infiltration of undifferentiated cells known as blasts that interfere with the production of normal cells. Vascular endothelial growth factor (VEGF) is persistently secreted from myeloid cells and high levels can be detected in patients' serum. Methods: Twenty-one AML patients, who were chemotherapy candidates were evaluated in a clinical trial. Serum VEGF was measured by ELISA. VEGFA, VEGFC mRNA and bone marrow MVD were measured in all patients before and after chemotherapy and then all results were analyzed. Results: There were 10 (48%) female and 11(52%) male patients ranged in age from 20 to 60 years, with an average age of 39.5 ±14.1 years. The mean amount of MVD was reduced from 10.8±3.6 before chemotherapy to7.6±3.3 after chemotherapy (P=0.008). VEGF was also reduced from 0.59±0.16 before chemotherapy to 0.24±0.03 after chemotherapy (P=0.005). Gene expression differences for VEGFA mRNA was 4.6±1.4, while it was 120.7±93.2 for VEGFC mRNA, showing the significance only for VEGA mRNA (P=0.02). Conclusion: Regarding reduced angiogenesis, we can conclude that anti-angiogenic preparations can be effective in treatment course of AML in combination with chemotherapy regimen.
کلیدواژه‌های انگلیسی مقاله AML,Angiogenesis,MVD,VEGF
نویسندگان مقاله زهره صناعت | zohreh sanaat
hematology amp;amp; oncology research center, tabriz university of medical sciences, tabriz ,iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

رضا خلیلی | reza khalili
hematology amp;amp; oncology research center, tabriz university of medical sciences, tabriz ,iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

شهره الماسی | shohreh almasi
immunology research center, tabriz university of medical sciences, tabriz, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

محمد رضا علیپرستی | mohammad reza aliparasti
hematology amp;amp; oncology research center, tabriz university of medical sciences, tabriz ,iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

سید محمد توانگر | seyed mohammad tavangar
pathology department, shariati hospital, tehran university of medical science, tehran, iran.

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

علی اکبر movasaghpoor | aliakbar movasaghpoor
hematology amp;amp; oncology research center, tabriz university of medical sciences, tabriz ,iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

فریبا کاظمی | fariba kazemi
hematology amp;amp; oncology research center, tabriz university of medical sciences, tabriz ,iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

آرش دوانی | arash davani
basic research team, kumc cardiovascular research institute, kansas city, kansas, usa.
نشانی اینترنتی http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/416
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات